Infinium Global Research Neuromodulation Market | Page 2

A latest report has been added to the wide database of Neuromodulation Market by Infinium Global Research. This report studies the
Neuromodulation Market by technology (deep brain, spinal cord, gastric, sacral, vagus nerve stimulation), application (chronic pain, parkinson’s
disease, dystonia, essential tremor, gastroparesis, OCD, refractory epilepsy, TRD, urinary fecal incontinence) market status and outlook of global
and major regions, from manufacturers, and end industries. The objective of the study is to identify market sizes of different segments &
countries in recent years and to forecast the values for the next six years. Neuromodulation Market provides opportunities in micro markets for
stakeholders to invest along with the detailed analysis of competitive landscape, latest trends, and product offerings of the major companies in
the Neuromodulation Market. According to report the global neuromodulation market is projected to grow at a CAGR of 10.9% over the forecast
period of 2017-2023.
Neuromodulation includes treatments that involve stimulation or administration of medications directly to the body’s nervous system for
therapeutic purposes. The target cells for stimulation include nerves in the central and peripheral nervous systems, the autonomic nervous
system, and the deep cell nuclei of the brain, resulting in modulation of their activity. Neuromodulation includes several modalities, and is a
cross-disciplinary approach to pain control and neurologic dysfunction. Neuromodulation can be used to treat movement disorders, spasticity,
and epilepsy, as well as pain syndromes. Devices are implanted which can either include drug delivery pumps or neural stimulators. The most
common type is spinal cord stimulation, which is used for back or lower extremity pain. Spinal cord stimulation involves electrical stimulation of
the spinal cord to interrupt pain signals from the spinal cord to the brain, and to trade a painful sensation with a more pleasant tingling sensation.
The technology has been present since the 1960s and in the past decade has become highly effective in the treatment of pain. In addition to
chronic pain relief, other neuromodulation treatments now used include deep brain stimulation for essential tremor, Parkinson’s disease,
dystonia, epilepsy and disorders such as depression, obsessive compulsive disorder and Tourette syndrome; sacral nerve stimulation for pelvic
disorders and incontinence; gastric and colonic stimulation for gastrointestinal disorders such as dysmotility or obesity; vagus nerve stimulation
for epilepsy, obesity or depression; carotid artery stimulation for hypertension; and spinal cord stimulation for ischemic disease such as angina
and peripheral vascular disease.
Market Insights
Rise in base of geriatric population, increasing number of patients with neurological disorders, strong product pipeline with various innovations,
increasing number of target applications, and increasing demand from emerging countries are the primary driving factors contributing for the
growth of this market. Neuromodulation is reversible and adjustable, in which physicians can on-invasively manage the electrical parameters
with a programmer to effectively control disease symptoms. However, there are certain factors which could hamper the growth of this market,
includes unfavorable reimbursement scenario and lack of sufficient number of trained professionals to treat disorders.